| Outcome Measures: |
Primary: Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12), Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405)., Baseline and Week 12 | Secondary: Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12), Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12), Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12), Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12), Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following; HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}., Baseline and Week 12|Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12), Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported., Baseline and Week 12|Number of Participants With Treatment-Emergent Adverse Events, Up to Week 12
|
